What Factors Influence a Site to Say "Yes" to a Trial
The design and completeness of the protocol and early and open communication with research center personnel are factors that most influence investigative site willingness to participate in a clinical study.
The design and completeness of the protocol and early and open communication with research center personnel are factors that most influence investigative site willingness to participate in a clinical study.
The Tufts Center for the Study of Drug Development (Tufts CSDD) conducted a survey in February and March 2010 among investigative sites around the world. More than 3500 sites completed the survey. Of the 13 factors rated, four of the most influential are related to protocol design: Availability of qualified, eligible study volunteers (the top rated by 63%); completeness of information about the study (55%); scientific attractiveness of the protocol (49%); and complexity of the protocol (29%).
Top Reasons Investigative Sites Participate in Studies
Two of the factors that most influence investigative site willingness to participate are communication related: completeness of study information (55%), and having early input into the protocol design (20%). Factors that had the least influence on site willingness to participate in a clinical study include the number of sites participating in the study (5% rate has "a great deal of influence"); type of electronic data capture system used (9%), and familiarity and experience with the contract research organization managing the study (16%).—Tufts Center for the Study of Drug Development, http://csdd.tufts.edu/.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
